Ultrasensitive prostate-specific antigen assays and their clinical application.

The contributions of Stamey in the area of prostate cancer diagnosis, monitoring, and treatment and in the prostatespecific antigen (PSA) literature are numerous and noteworthy.’ His accompanying Opinion article [1] deals with aspects of analytical performance as well as clinical interpretations of PSA assays and raises concern that clinicians may be misled by recently published data. We agree with many of his concerns and disagree with others. In areas of disagreement, we would like to offer alternative views that are based on extensive published and unpublished data from our own research group.